DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Gastrointestinale Onkologie » Leber/Galle

Alle Linien

FIDES-01
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) (Aktiv)

GAIN
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (GAIN) (Aktiv)

IMMULAB
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) (Aktiv)

IMMUWHY (AIO-HEP-0119/ass)
A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care (Aktiv)

Immunib
Immunotherapy With Nivolumab in Combination With Lenvatinib for Advanced Stage Hepatocellular Carcinoma (Aktiv)

NFAT
Validierung der expressionsanalyse nfat-regulierter Gene (Aktiv)

NIFE
Nal-IRI, 5-Fluorouracil und Leucovorin versus Gemcitabin plus Cisplatin bei fortgeschrittenem Gallenwegskarzinom (Aktiv)

Erstlinie

CONTRAIL I
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up (Aktiv)

DEMAND
Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab (Aktiv)

HERACLES
Hepatocellular carcinoma stereotactic Radiotherapy Clinical Evaluation Study (Aktiv)

IMMUWIN (AIO-HEP-0319/ass)
Eine Phase-II-Studie zur Immuntherapie mit Durvalumab und Tremelimumab in Kombination mit entweder Y-90 SIRT oder TACE bei Patienten mit Leberzellkarzinom im Zwischenstadium mit einem „Pick-the-Winner“ Design - IMMUWIN (Aktiv)

PROMETHEUS-01
Evaluating the treatment of patients with hepatocellular carcinoma (Aktiv)

PROOF
Eine multizentrische, offene, randomisierte, kontrollierte Phase 3 Studie mit oRal verabreichtem Infigratinib im Vergleich zu Gemcitabin mit Cisplatin bei Patienten mit fortgeschrittenem/metastasierendem oder inOperablem GallengangskarzinOm mit FGFR2-Genfusionen/Translokationen: Die PROOF -Studie (Aktiv)

WO41535
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (Aktiv)

Zweitlinie oder später

ACTICCA-1
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Resection of Biliary Tract Cancer (Aktiv)

AIO-HEP-0116, NALIRICC
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC) (Aktiv)

AURORA
Study of Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) after treatment failure of, or intolerabiliy to first line treatment. (Aktiv)

CBGJ398X2204
This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with FGFR genetic alterations. (Aktiv)

CaPture
Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 Inhibitors (Aktiv)

CaboRISE
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Compensated Liver Cirrhosis (Aktiv)

DKN-01 inhibition in advanced liver cancer
A clinical Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and genetic alteration in WNT signaling pathway (Aktiv)

EMERALD-2
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment (Aktiv)

IRIBIL
FOLFIRI versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (Aktiv)

IRITACE
Image-guided, non-surgical procedure in combination with different chemotherapeutics in patients with Hepatocellular carcinoma not amenable to curative treatment (Aktiv)

KEYNOTE-937
A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (Aktiv)

PARLIM-Studie, AIO-KRK-0314
Panitumumab after Resection of Liver Metastases from Colorectal Cancer (Aktiv)

PHITT
Paediatric Hepatic International Tumour Trial (Aktiv)

SORATRAM
Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de